isolated antibody, composition, isolated nucleic acid molecule, vector, host cell, method for producing an antibody, hybridoma, methods for alleviating one or more symptoms of disease, and for decreasing or inhibiting hlight binding to hvem, ltbr, dcr3 or any combination thereof, and to decrease or inhibit secretion of ccl20, il-8, rantes or any combination thereof, and
KIRIN PHARMA KABUSHIKI KAISHA;LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY
发明人:
STEVEN W. GRANGER,SHINICHIRO KATO,CARL F. WARE
申请号：
BRPI0716088
公开号：
BRPI0716088A2
申请日:
2007.08.24
申请国别(地区):
BR
年份:
2013
代理人:
摘要：
Provided herein are antibodies, such as fully human antibodies, that immunospecifically bind to an hLIGHT polypeptide. Also provided are isolated nucleic acids encoding antibodies, such as fully human antibodies, that immunospecifically bind to a hLIGHT polypeptide. Further provided are vectors and host cells comprising nucleic acids encoding antibodies, such as fully human antibodies, that immunospecifically bind to a hLIGHT polypeptide. Also provided are methods of making antibodies, such as fully human antibodies, that immunospecifically bind to a hLIGHT polypeptide. Also provided herein is a method of treating a hLIGHT - mediated disease in a subject comprising administering to the subject an antibody, such as a fully human antibody, that immunospecifically binds to a hLIGHT polypeptide. In preferred embodiments, that anti-hLIGHT antibodies provided herein will ameliorate, neutralize or otherwise inhibit hLIGHT biological activity in vitro (e.g., the hLIGHT-mediated production or secretion of CCL20, IL-8 or RANTES from a cell expressing a hLIGHT receptor). Also provided herein is a method for the detection of hLIGHT in a sample as well as a method for ameliorating, neutralizing or otherwise inhibiting hLIGHT activity, e.g., in a human subject suffering from a disorder in which hLIGHT activity is detrimental.
